Glucocorticoid-induced osteopenia in adolescent heart transplant recipients

J Heart Lung Transplant. 2000 Sep;19(9):840-5. doi: 10.1016/s1053-2498(00)00159-5.

Abstract

Background: Glucocorticoid-induced cushingoid symptoms, including osteopenia and osteoporosis are well-documented in adult heart transplant recipients (HTR). Bone mineral density (BMD) of the axial skeleton is diminished by 10% to 20% within 60 days after transplantation (Tx) and most adult HTR fulfill World Health Organization criteria for osteoporosis (BMD > 2.5 SD below norm). At present, we do not know whether glucocorticoids have similar deleterious effects in adolescent HTR.

Methods: To determine the consequences of glucocorticoid immunosuppression on regional bone mineral density (BMD) and biochemical markers of bone metabolism in adolescent HTR, we studied 19 patients (aged 16 +/- 3) at 19 months (group mean) after Tx. We measured BMD (hydroxyapatite g/cm(2)) of the total body, lumbar spine, and pelvis using dual-energy X-ray absorptiometry (Lunar). Serum levels of bone-specific alkaline phosphatase and pyridinoline cross-links were determined by enzyme immunoassay in serum kits.

Results: The BMD of the lumbar spine (-12%), femur neck (-13%), femur trochanter (-12%), and ward's triangle (-16%) were significantly (p < 0.05) lower in adolescent HTR than age- and gender-matched norms. Serum levels of alkaline phosphatase (29 +/- 6 vs 22 +/- 3 U/liter) and pyridinoline cross-links (5.3 +/- 1.1 vs 3.8 +/- 0.7 mmol/liter) were significantly (p < 0.05) elevated in adolescent HTR, compared with age- and gender-matched controls studied in our laboratory.

Conclusions: Our cross-sectional results demonstrate that BMD of the axial skeleton in adolescent HTR is significantly lower (-10% to 20%) than age-matched norms and that serum biochemical markers of bone metabolism are significantly elevated, suggesting accelerated bone turnover.

MeSH terms

  • Absorptiometry, Photon
  • Adolescent
  • Adult
  • Alkaline Phosphatase / blood
  • Amino Acids / blood
  • Bone Density / drug effects*
  • Bone Diseases, Metabolic / blood
  • Bone Diseases, Metabolic / chemically induced*
  • Child
  • Cross-Sectional Studies
  • Female
  • Glucocorticoids / adverse effects*
  • Glucocorticoids / therapeutic use
  • Heart Transplantation*
  • Humans
  • Male
  • Methylprednisolone / adverse effects*
  • Methylprednisolone / therapeutic use

Substances

  • Amino Acids
  • Glucocorticoids
  • pyridinoline
  • Alkaline Phosphatase
  • Methylprednisolone